

Effect of Narrowband Ultraviolet B with Methotrexate on T Cell Receptor Gamma Gene Rearrangement in the Skin and Blood of Mycosis Fungoides Patients

Thesis

***Submitted for Fulfillment of MD Degree in
Dermatology***

By

Sara Bahaa El Din Mahmoud

M.B B.Ch., M.Sc. of Dermatology

Under Supervision of

Dr. Hesham Abd El Moaty Zaher

Professor of Dermatology

Faculty of Medicine – Cairo University

Dr. Omar Soliman El Safoury

Assistant Professor of Dermatology

Faculty of Medicine – Cairo University

Dr. Amany Zaki El Ramly

Assistant Professor of Dermatology

Faculty of Medicine – Cairo University

Dr. Olfat Gamil Shaker

Professor of Biochemistry

Faculty of Medicine – Cairo University

Faculty of Medicine

Cairo University

2010

Abstract

Mycosis fungoides (MF) is the most common subtype of cutaneous T cell lymphomas (CTCLs). T cell receptor (TCR) γ gene rearrangement, demonstrated by polymerase chain reaction (PCR), is the most effective method to evaluate clonality in T cell malignant neoplasms. The aim of this study was to determine whether the presence of a dominant T cell clone in the blood of stage IA and IB MF patients is associated with more severe clinical picture and/or resistance to therapy, which was previously investigated but on all stages of MF including Sézary syndrome (SS) "collectively", and to investigate the PCR outcome in the skin and blood after treatment with narrowband ultraviolet B (NB-UVB) combined with methotrexate. Thirty participants with stage I MF were included in this study. They received 36 NB-UVB sessions (3 sessions/week) in combination with methotrexate tablets 0.3 mg/kg/week for 3 months. Participants were evaluated before and after treatment regarding clinical picture, epidermotropism, density of dermal infiltrate, skin and blood examination for TCR γ gene rearrangement by PCR. A dominant T cell clone was detected in the skin of 21/28 (75%) of participants and disappeared from 9/21 (42.8%) after treatment. Regarding the blood, a dominant T cell clone was detected in 14/28 (50%) of participants and disappeared from 6/14 (42.8%) after treatment. Participants were divided into 2 groups according to pre-treatment blood PCR: group I (negative) and group II (positive). Our results demonstrated that collectively, both negative post-treatment skin PCR and negative post-treatment blood PCR were significantly associated with better clinical outcome and less dense post-treatment dermal infiltrate. However, they could not show the prognostic value of pre-treatment skin or blood PCR in the prediction of post-treatment clinical and histopathological outcome.

Key words: Mycosis fungoides-TCR γ gene rearrangement-clonality-prognosis

Acknowledgement

Thanks to ALLAH, the most kind and the most merciful, who lightened my path and granted me the ability to accomplish this work.

Words can never express my hearty thanks and indebtedness to Dr. Hesham Zaher, professor of dermatology, Faculty of Medicine, Cairo University, for his valuable supervision, continuous support and encouragement.

I am deeply indebted to Dr. Omar El Safoury, assistant professor of dermatology, Faculty of Medicine, Cairo University, for his valuable advice, great help and excellent supervision.

I am profoundly grateful to Dr. Amany El Ramly, assistant professor of dermatology, Faculty of Medicine, Cairo University, for her valuable supervision, endless support and great effort that added a lot to this work.

I am deeply grateful to Dr. Olfat Shaker, professor of biochemistry, Faculty of Medicine, Cairo University, for her valuable supervision, generous help and continuous support.

Words can never express my deep gratitude and sincere thanks to Prof. Mohamed El Darouty, professor of dermatology, Faculty of Medicine, Cairo University, for generously giving much of his precious time for evaluation of all the histopathological slides.

Special thanks to Dr. Eman El Nabarawy and Dr. Marwa Fawzi, lecturers of dermatology, Faculty of Medicine, Cairo University for evaluation of the histopathological slides and setting of a histopathological score for all patients enrolled in this study.

I am deeply grateful to Dr. Amira Zayed, assistant professor of dermatology, Faculty of Medicine, Cairo University, for her great help in the revision of this work.

I would like to thank all my family members for their patience, continuous encouragement, generous help, enthusiastic support and love.

Finally, I would like to thank all my professors and colleagues in the dermatology department for their help and support.

List of Abbreviations

BB	broadband
C	constant
CBC	complete blood count
CCL	chemokine ligands
CCR	chemokine receptor
cDNA	complementary deoxyribonucleic acid
CDR	complementarity determining region
CLA	cutaneous lymphocyte antigen
CMV	cytomegalovirus
CT	computed tomography
CTCL	cutaneous T cell lymphoma
D	diversity
DNA	deoxyribonucleic acid
EBV	Epstein-Barr virus
ECP	extracorporeal photopheresis
EORTC	European organization for research and treatment of cancer
FDA	Food and Drug Administration
FST	Fitzpatrick skin type
HIV	human immunodeficiency virus
HTLV	human T-cell lymphotropic virus
IL	interleukin
ISCL	international society for cutaneous lymphoma
J	joining
LN	lymph node
MED	Minimal erythema dose
MF	Mycosis fungoides
MHC	major histocompatibility complex
NB	Narrowband

NCI	National Cancer Institute
NSAIDs	non-steroidal anti-inflammatory drugs
PCR	polymerase chain reaction
PUVA	psoralen plus ultraviolet A
RAG	Recombinase activating gene
SB	Southern blotting
SS	Sézary syndrome
TBI	tumor burden index
TCR	T-cell receptor
TdT	terminal deoxyribonucleotidyl transferase
TGF	transforming growth factor
Th2	T-helper 2
TNF	tumor necrosis factor
TNM	tumor-node- metastasis
TNMB	tumor-node- metastasis-blood
TSEBT	total skin electron beam therapy
UV	ultraviolet
V	variable
WBC	white blood cell

List of Figures

Fig. no.		Page
1	Mycosis Fungoides: A Cancer of Skin-Homing T Cells	8
2	T cell receptor	24
3	The structure of the T cell antigen receptor	25
4	Steps in the maturation and selection of MHC-restricted T lymphocytes	30
5	Structure of methotrexate and tetrahydrofolate	39
6	Comparison between pre-treatment clinical evaluation of groups I (negative blood PCR-0) and II (positive blood PCR-0)	77
7	Comparison between clinical response in cases with negative and positive blood PCR-36	91
8	Comparison between histopathological response in cases with negative and positive blood PCR-36	92
9	Comparison between post-treatment dermal infiltrate in cases with negative and positive blood PCR-36	94
10	Comparison between clinical response in cases with negative and positive skin PCR-36	95
11	Comparison between histopathological response in cases with negative and positive skin PCR-36	96
12	Comparison between post-treatment dermal infiltrate in cases with negative and positive skin PCR-36	98
13	A male patient with plaque stage MF before and after treatment	101

14	A photomicrograph of a section in the skin of the same patient before and after treatment (H & E)	102
15	A female patient with hypopigmented MF before and after treatment	103
16	A photomicrograph of a section in the skin of the same patient before and after treatment (H & E)	104
17	V γ 1–8 PCR products run on 2% agarose gel from skin biopsies of MF patients before treatment	105
18	V γ 1–8 PCR products run on 2% agarose gel from skin biopsies of MF patients after treatment	105
19	V γ 1–8 PCR products run on 2% agarose gel from blood samples of MF patients before treatment	106
20	V γ 1–8 PCR products run on 2% agarose gel from blood samples of MF patients after treatment	106

List of Tables

Table no.		Page
1	Algorithm for diagnosis of early MF	16
2	TNMB classification of CTCL	17
3	Staging system of CTCL	17
4	ISCL/EORTC revisions to the classification and staging of MF/SS	18
5	Indications and contraindications of methotrexate	43
6	Methotrexate drug interactions	47
7	Clinical items evaluated for plaque MF during follow up	60
8	Clinical items evaluated for patch MF during follow up	61
9	Clinical items evaluated for hypopigmented MF during follow up	62
10	Histopathological items evaluated during follow up	63
11	Summary of the data of the participants.	66
12	Comparison between clinical evaluation of all participants at sessions 0 and 36	68
13	Comparison between epidermotropism of all participants at sessions 0 and 36	69
14	Comparison between dermal infiltrate of all participants at sessions 0 and 36	69
15	Comparison between skin PCR of all participants at sessions 0 and 36	70
16	Comparison between blood PCR of all participants at sessions 0 and 36	70

Table no.		Page
17	Comparison between clinical evaluation of group I (negative pre-treatment blood PCR) at sessions 0 and 36	71
18	Comparison between epidermotropism in group I (negative pre-treatment blood PCR) at sessions 0 and 36	71
19	Comparison between dermal infiltrate in group I (negative pre-treatment blood PCR) at sessions 0 and 36	72
20	Comparison between the skin PCR in group I (negative pre-treatment blood PCR) at sessions 0 and 36	72
21	Comparison between clinical evaluation of group II (positive pre-treatment blood PCR) at sessions 0 and 36	73
22	Comparison between epidermotropism in group II (positive pre-treatment blood PCR) at sessions 0 and 36	74
23	Comparison between dermal infiltrate in group II (positive pre-treatment blood PCR) at sessions 0 and 36	74
24	Comparison between skin PCR in group II (positive pre-treatment blood PCR) at sessions 0 and 36	75
25	Comparison between pre-treatment clinical evaluation of groups I (negative blood PCR-0) and II (positive blood PCR-0)	76
26	Comparison between pre-treatment epidermotropism in groups I (negative blood PCR-0) and II (positive blood PCR-0)	77
27	Comparison between pre-treatment dermal infiltrate in groups I (negative blood PCR-0) and II (positive blood PCR-0)	78
28	Comparison between pre-treatment skin PCR in groups I (negative blood PCR-0) and II (positive blood PCR-0)	78

29	Comparison between post-treatment clinical evaluation of groups I (negative blood PCR-0) and II (positive blood PCR-0)	79
30	Comparison between post-treatment epidermotropism in groups I (negative blood PCR-0) and II (positive blood PCR-0)	80
31	Comparison between post-treatment dermal infiltrate in groups I (negative blood PCR-0) and II (positive blood PCR-0)	80
32	Comparison between post-treatment skin PCR in groups I (negative blood PCR-0) and II (positive blood PCR-0)	81
33	Comparison between clinical response in groups I (negative blood PCR-0) and II (positive blood PCR-0)	81
34	Comparison between histopathological response in groups I (negative blood PCR-0) and II (positive blood PCR-0)	82
35	Comparison between pre-treatment clinical evaluation of cases with negative and positive skin PCR-0	83
36	Comparison between pre-treatment epidermotropism in cases with negative and positive skin PCR-0	84
37	Comparison between pre-treatment dermal infiltrate in cases with negative and positive skin PCR-0	84
38	Comparison between post-treatment clinical evaluation of cases with negative and positive skin PCR-0	85
39	Comparison between post-treatment epidermotropism in cases with negative and positive skin PCR-0	86
40	Comparison between post-treatment dermal infiltrate in cases with negative and positive skin PCR-0	86

41	Comparison between clinical response in cases with negative and positive skin PCR-0	87
42	Comparison between histopathological response in cases with negative and positive skin PCR-0	88
43	Comparison between clinical response in cases with negative and positive blood PCR-36	91
44	Comparison between histopathological response in cases with negative and positive blood PCR-36	92
45	Comparison between post-treatment epidermotropism in cases with negative and positive blood PCR-36	93
46	Comparison between post-treatment dermal infiltrate in cases with negative and positive blood PCR-36	94
47	Comparison between clinical response in cases with negative and positive skin PCR-36	95
48	Comparison between histopathological response in cases with negative and positive skin PCR-36	96
49	Comparison between post-treatment epidermotropism in cases with negative and positive skin PCR-36	97
50	Comparison between post-treatment dermal infiltrate in cases with negative and positive skin PCR-36	98

List of Contents

	Page
Introduction and aim of work	1
Review of literature:	3
Mycosis fungoides	3
T cell receptors	23
Narrowband ultraviolet B	32
Methotrexate	38
Participants and methods	50
Results	65
Case presentation	101
Discussion	107
Summary	116
References	119
Arabic summary	

INTRODUCTION

Cutaneous T cell lymphomas (CTCLs) are a group of diseases characterized by several features, including the proliferation of skin homing T-cells, the monoclonal nature of these T-cells and the potential of almost all forms to transform into high grade T-cell lymphoma (*Girardi et al., 2004*). Mycosis fungoides (MF) is the most common variant of primary CTCL, generally associated with an indolent clinical course and characterized by well-defined clinicopathological features (*Whittaker and Mackie, 2004*).

Although the disease is limited to the skin in its early manifestations, it was reported that 50% of patients with early disease have clones of T cells in their blood (*Hwong et al., 2001*).

All the tumor cells carry an identical T-cell receptor (TCR), a marker that can be used for diagnostic and prognostic monitoring (*Berger et al., 1998*).

The TCR is the antigen-specific receptor for T cells. During differentiation, each T cell undergoes rearrangement of its TCR genes. This results in novel nucleotide sequences that constitute a unique signature or fingerprint for each T cell and all its clonal progeny (*Wood, 2001a*).

Several studies reported that patients with dominant T cell clones detected by polymerase chain reaction (PCR) in the skin and/or blood have a worse prognosis (*Delfau-Larue et al., 1998a & Fraser-Andrews et al., 2000 & Beylot-Barry et al., 2001 & Vega et al., 2002*).

The choice of initial treatment for the MF patient depends on the stage of the disease as well as the general condition and age of the patient. There are very few published studies that could form the basis for evidence-based therapy, mainly because of the variation between individual patients in disease pattern and progress (*Whittaker and MacKie, 2004*).

Narrowband ultraviolet B (NB-UVB) therapy is an effective modality for patients with early-stage MF (*Diederer et al., 2003*).

Low-dose methotrexate has been shown to be particularly effective in patients with erythrodermic MF (*Zackheim et al., 1996*), in addition, its use has been suggested for refractory early-stage (*Zackheim et al., 2003*) as well as in stage IB MF (*McFarlane et al., 2005*).

Aim of work:

The aim of this study was to determine whether the presence of a dominant T cell clone in the blood of stage IA and IB MF patients is associated with more severe clinical picture and/or resistance to therapy, which was previously investigated but on all stages of MF including SS "collectively", and to investigate the PCR outcome in the skin and blood after treatment with NB-UVB combined with methotrexate.